Takeda Pharmaceutical Company (TKDA) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Takeda Pharmaceutical Company DE:TKDA is currently developing the following drugs: Rusfertide, Ptg-300, Zasocitinib, Tak-279, Rusfertide, Tak-360, Elritercept, Tak-226, Mezagitamab, Tak-079, Epoetin Alfa, Elritercept, Tak-505, Tak-279, Zasocitinib, Tak-755, Tak-861, Tak-226, Elritercept, Zasocitinib, Tak-781, Vortioxetine Tablets, Tak-188, Ibi363, Control Arm, Tetravalent Dengue Vaccine, Igi, 10%, Mezagitamab, Tak-411, Active Comparator, Zasocitinib, Vedolizumab Iv, Vedolizumab Sc, Tdv, Fruquintinib, Elritercept, Vedolizumab, Concomitant Antibiotic Therapy, Maribavir, Vedolizumab Sc, No Intervention, Tak-853, Mirvetuximab Soravtansine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.